IP Library Granted Patent US 9,134,313
Granted Patent B2
US 9,134,313 · App. 12/480,983 · Granted Sep 15, 2015

Method of detecting colorectal cancer of stages 0 to I

Inventors: Masao Kawakita (Tokyo, JP); Kyoko Hiramatsu (Tokyo, JP); Keiichi Takahashi (Saitama, JP); Naotaka Hamasaki (Fukuoka, JP); Koji Yamaguchi (Fukuoka, JP); Tsunehisa Kaku (Fukuoka, JP); Koichiro Muta (Fukuoka, JP); Munechika Enjoji (Fukuoka, JP); Seiji Naito (Fukuoka, JP); Jun Hayashi (Fukuoka, JP); Shoshu Mitsuyama (Fukuoka, JP); Hiroyuki Yamashita (Oita, JP); Toru Inoue (Fukuoka, JP); Masato Kato (Fukuoka, JP)
Assignees: Tokyo Metropolitan Organization For Medical Research; CRC Inc.; Tokyo Metropolitan Government; Trans Genic Inc.
G01N33/574C07K16/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,134,313
App. No.
12/480,983
Granted
Sep 15, 2015
Kind
B2
Abstract

A tumor marker comprising diacetylspermine, and a method of evaluating the state of a tumor, comprising reacting an antibody to diacetylspermine with a biological sample to thereby detect diacetylspermine and evaluating the state of the tumor using the obtained detection results as an indicator.

Claims (15)

1. A method of detecting colorectal cancer of stages 0 to I, an early tumor, comprising

taking a biological sample from a patient suspected of having the colorectal cancer or subject of a health examination;

contacting the biological sample with an antibody that binds N 1 ,N 12 -diacetylspermine, thereby binding the antibody with N 1 ,N 12 -diacetylspermine in the biological sample;

quantitatively determining N 1 ,N 12 -diacetylspermine contained in the biological sample on the basis of quantitative determination results of the antibody which is bound to N 1 ,N 12 -diacetylspermine; and

detecting the presence or absence of the colorectal cancer of stages 0 to I using the quantitative determination results of N 1 ,N 12 -diacetylspermine as an indicator.

2. The method according to claim 1 , wherein the biological sample is urine.

3. The method according to claim 1 , wherein the cancer detected is colorectal cancer of stages 0 to I.

4. A method of detecting colorectal cancer of stages 0 to I, an early tumor, comprising

providing a N 1 ,N 12 -diacetylspermine specific antibody which has at least one property selected from the group consisting of (a) a cross-reactivity with N 1 -acetylspermidine of 0.1% or less, and (b) a total interference on the measurement of N 1 ,N 12 -diacetylspermine specific antibody caused by its cross-reaction with N 1 -acetylspermidine, N 8 -acetylspermidine, N 1 ,N 8 -diacetylspermidine, and acetylspermine present in urine of 5% or less;

contacting a biological sample from a patient suspected of having the colorectal cancer or subject of a health examination with the antibody, thereby binding the antibody with N 1 ,N 12 -diacetylspermine in the biological sample;

quantitatively determining N 1 ,N 12 -diacetylspermine contained in the biological sample on the basis of quantitative determination results of the antibody bound to N 1 ,N 12 -diacetylspermine; and

detecting the presence or absence of the colorectal cancer of stages 0 to I using the quantitative determination results of N 1 ,N 12 -diacetylspermine as an indicator.

5. The method according to claim 4 , wherein the biological sample is urine.

6. The method according to claim 4 , wherein the cancer detected is colorectal cancer of stages 0 to I.

7. The method according to claim 4 , wherein the total interference (b) is 3% or less.

Assignments (2)
CHANGE OF ADDRESS OF ASSIGNEE Recorded Mar 10, 2017
From: TRANS GENIC INC.
To: TRANS GENIC INC.
Reel/Frame 041962/0995 →
CHANGE OF NAME Recorded Sep 27, 2011
From: TOKYO METROPOLITAN ORGANIZATION FOR MEDICAL RESEARCH
To: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE
Reel/Frame 026978/0183 →
Priority Claims (2)
JP 2003-065562 · Mar 11, 2003 · national
JP 2003-367568 · Oct 28, 2003 · national
Continuity (2)
Division 10548658
Related Publication 20090298098A1 · Dec 3, 2009